284 related articles for article (PubMed ID: 30115693)
1. IFNγ PET Imaging as a Predictive Tool for Monitoring Response to Tumor Immunotherapy.
Gibson HM; McKnight BN; Malysa A; Dyson G; Wiesend WN; McCarthy CE; Reyes J; Wei WZ; Viola-Villegas NT
Cancer Res; 2018 Oct; 78(19):5706-5717. PubMed ID: 30115693
[TBL] [Abstract][Full Text] [Related]
2. CD8
Seo JW; Tavaré R; Mahakian LM; Silvestrini MT; Tam S; Ingham ES; Salazar FB; Borowsky AD; Wu AM; Ferrara KW
Clin Cancer Res; 2018 Oct; 24(20):4976-4987. PubMed ID: 29967252
[No Abstract] [Full Text] [Related]
3. Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes.
Natarajan A; Mayer AT; Xu L; Reeves RE; Gano J; Gambhir SS
Bioconjug Chem; 2015 Oct; 26(10):2062-9. PubMed ID: 26307602
[TBL] [Abstract][Full Text] [Related]
4. Interferon gamma immunoPET imaging to evaluate response to immune checkpoint inhibitors.
Hackett JB; Ramos N; Barr S; Bross M; Viola NT; Gibson HM
Front Oncol; 2023; 13():1285117. PubMed ID: 38130991
[TBL] [Abstract][Full Text] [Related]
5. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.
Linch SN; Kasiewicz MJ; McNamara MJ; Hilgart-Martiszus IF; Farhad M; Redmond WL
Proc Natl Acad Sci U S A; 2016 Jan; 113(3):E319-27. PubMed ID: 26729864
[TBL] [Abstract][Full Text] [Related]
6. IFNγ-induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody.
Li J; Ybarra R; Mak J; Herault A; De Almeida P; Arrazate A; Ziai J; Totpal K; Junttila MR; Walsh KB; Junttila TT
Clin Cancer Res; 2018 Dec; 24(24):6447-6458. PubMed ID: 29950350
[TBL] [Abstract][Full Text] [Related]
7. Immuno-PET imaging of tumor-infiltrating lymphocytes using zirconium-89 radiolabeled anti-CD3 antibody in immune-competent mice bearing syngeneic tumors.
Beckford Vera DR; Smith CC; Bixby LM; Glatt DM; Dunn SS; Saito R; Kim WY; Serody JS; Vincent BG; Parrott MC
PLoS One; 2018; 13(3):e0193832. PubMed ID: 29513764
[TBL] [Abstract][Full Text] [Related]
8. Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells.
Bae EA; Seo H; Kim BS; Choi J; Jeon I; Shin KS; Koh CH; Song B; Kim IK; Min BS; Han YD; Shin SJ; Kang CY
Cancer Res; 2018 Sep; 78(18):5315-5326. PubMed ID: 30012672
[TBL] [Abstract][Full Text] [Related]
9. Immuno-PET Monitoring of CD8
Alsaid H; Cheng SH; Bi M; Xie F; Rambo M; Skedzielewski T; Hoang B; Mohanan S; Comroe D; Gehman A; Hsu CY; Farhangi K; Tran H; Sherina V; Doan M; Groseclose MR; Hopson CB; Brett S; Wilson IA; Nicholls A; Ballas M; Waight JD; Jucker BM
Mol Imaging Biol; 2023 Jun; 25(3):528-540. PubMed ID: 36266600
[TBL] [Abstract][Full Text] [Related]
10. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
11. Imaging of Activated T Cells as an Early Predictor of Immune Response to Anti-PD-1 Therapy.
Levi J; Lam T; Goth SR; Yaghoubi S; Bates J; Ren G; Jivan S; Huynh TL; Blecha JE; Khattri R; Schmidt KF; Jennings D; VanBrocklin H
Cancer Res; 2019 Jul; 79(13):3455-3465. PubMed ID: 31064845
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of an ImmunoPET Tracer for IL-12 in a Preclinical Model of Inflammatory Immune Responses.
Viola NT; Glassbrook JE; Kalluri JR; Hackett JB; Wicker MN; Sternberg J; Gibson HM
Front Immunol; 2022; 13():870110. PubMed ID: 35634303
[TBL] [Abstract][Full Text] [Related]
13. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging.
Maute RL; Gordon SR; Mayer AT; McCracken MN; Natarajan A; Ring NG; Kimura R; Tsai JM; Manglik A; Kruse AC; Gambhir SS; Weissman IL; Ring AM
Proc Natl Acad Sci U S A; 2015 Nov; 112(47):E6506-14. PubMed ID: 26604307
[TBL] [Abstract][Full Text] [Related]
14. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
15. Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model.
Natarajan A; Mayer AT; Reeves RE; Nagamine CM; Gambhir SS
Mol Imaging Biol; 2017 Dec; 19(6):903-914. PubMed ID: 28247187
[TBL] [Abstract][Full Text] [Related]
16. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
17. An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy.
Tavaré R; Escuin-Ordinas H; Mok S; McCracken MN; Zettlitz KA; Salazar FB; Witte ON; Ribas A; Wu AM
Cancer Res; 2016 Jan; 76(1):73-82. PubMed ID: 26573799
[TBL] [Abstract][Full Text] [Related]
18. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
[TBL] [Abstract][Full Text] [Related]
19. Dynamic Tumor-Specific MHC-II Immuno-PET Predicts the Efficacy of Checkpoint Inhibitor Immunotherapy in Melanoma.
Yang Z; Li F; Huang Y; Yin N; Chu J; Ma Y; Pettigrew RI; Hamilton DJ; Martin DR; Li Z
J Nucl Med; 2022 Nov; 63(11):1708-1714. PubMed ID: 35210298
[TBL] [Abstract][Full Text] [Related]
20. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]